InsidersTradesSigma
Hansa Biopharma AB: management transactions · Finland · FIN-FSA
FI:hansa-biopharma-ab-f1568bSE0002148817FI·FIN-FSAMcap 2.9Bn€Healthcare
Browse the full directors' dealings record of Hansa Biopharma AB, a publicly traded company based in Finland. Shares trade on FI FI, under the authority of FIN-FSA. Operating in the Healthcare sector, Hansa Biopharma AB has published 1 reports. Market capitalisation: €2.9bn. The latest transaction was reported on 10 November 2025 — Purchase. Among the most active insiders: Charles Ballantyne. All data is openly available.
1
Insider Decl.
0
Thresholds
€70,854
1 ops.
Buy Volume
·
0 ops.
Sell Volume
Financial data
FY ended December 2025 · cache
28.84 €
Analyst consensus
7 analystsStrong buy
35.00 €Target 75.00 €(+160%)103.00 €
Income statement
Revenue222.3 M€
Gross profit138.7 M€62% margin
Net income−534.1 M€-240.3% margin
Valuation
PER (forward)-7.2x
Beta1.50
Balance sheet & cash
Market cap2.88 Bn€
Total debt938.7 M€
Free Cash Flow−549.2 M€
Profitability & ownership
ROA-38.2%
% insiders9.8%
% institutions47.5%
Last declaration on 10 November 2025
Declarations1 total
Executives●Purchase31FIN-FSA
C
Charles BallantyneArbetstagarrepresentant i styrelsen eller arbetstagarsuppleant, Ekonomichef/finanschef/finansdirektör€70,85425,000 shares@ €2.83410.0025% mcap100.0% of flow
Aktie
FI:A003T468-1·
Ideal exit: 4 Aug 2026 (T+270)
1 of 1 declaration